No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMGN240726C345000
- 0.64
- -0.14-17.95%
15min DelayClose Jul 19 15:59 ET
0.64High0.32Low
0.50Open0.78Pre Close336 Volume622 Open Interest345.00Strike Price14.27KTurnover27.09%IV4.33%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.64Extrinsic Value100Contract SizeAmericanOptions Type0.1024Delta0.0174Gamma669.27Leverage Ratio-0.1869Theta0.0044Rho68.55Eff Leverage0.0678Vega
Intraday
- 5D
- Daily
News
Here Are Big Pharma's Leading Blockbuster Makers
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
Express News | Amgen Says Currently Assessing Global IT Outage Impact And Working To Recover Impacted Systems As Quickly As Possible
Express News | Amgen Inc - Are Currently Assessing Global It Outage Impact and Are Working to Recover Impacted Systems as Quickly as Possible.
Jefferies Adjusts Price Target on Amgen to $380 From $375
Amgen (AMGN) has an average rating of outperform and price targets ranging from $170 to $380, according to analysts by Capital IQ.Price: 333.74, Change: +2.77, Percent Change: +0.84
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $380
Jefferies analyst Michael Yee maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $375 to $380.According to TipRanks data, the analyst has a success rate of 45.8% and a
Comments
$Amgen(AMGN.US$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
4
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
16
I hate these days. I know it's investing & I'm long with my bets, but I have better, more exciting days when I don't see a lot of red. Sucks. And, I was terminated from my job in April & having a hard time getting unemployment. I was a 1099 contractor on that job & the department of labor doesn't know how to process my claim. This is making me low on hard cash & I'm going to have to sell a position or 2, and I DO NOT WANT TO DO THAT, especially with $Esperion Therapeutics (ESPR.US)$. I read...
7
3
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Read more